Resources
Resources
We are currently involved in two clinical studies NTC05857969 & NCT06024603. Our mission is to make this platform accessible outside of a clinical trial by Q3 2024. Giving those with the rarest cancers a fighting chance. A treatment plan for every type of cancer including all solid and all liquid tumors. The First Ascent Team has a growing body of research and publications, as well as useful guidelines and updates for our patients, physicians and partners. If you have a question that is not answered here, we would be happy to discuss – you can contact us here.
We are currently involved in two clinical studies NTC05857969 & NCT06024603. Our mission is to make this platform accessible outside of a clinical trial by Q3 2024. Giving those with the rarest cancers a fighting chance. A treatment plan for every type of cancer including all solid and all liquid tumors. The First Ascent Team has a growing body of research and publications, as well as useful guidelines and updates for our patients, physicians and partners. If you have a question that is not answered here, we would be happy to discuss – you can contact us here.
Patients –
Soon Getting Started with Us is Four Simple Steps!
1. Start
Start the conversation with your provider about alternate treatment options through First Ascent Biomedical.
2. Ship
We work with your doctor to ship a live tumor tissue sample overnight to First Ascent’s cutting-edge CLIA certified laboratories.
3. Test
We test drugs on your cancer cells to identify your cancer’s unique vulnerabilities, supported by DNA and RNA analysis.
1. Deliver
Your top treatment options with the underlying data and evidence are delivered to your physician as a concise and actionable report, complete with rationale, on average in 10 days.
For more detail see our Frequently Asked Questions.
First Ascent’s Ex Vivo Drug Response Identification & Validation Engine – xDRIVE Platform is a first-in-kind medical oncology decision support system that integrates functional drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping resulting in prioritized therapeutic solutions tailored to the patient’s tumor vulnerabilities and tested based on tests run on the patient’s own cells.
The Latest First Ascent Biomedical News
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex [...]
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and [...]
Groundbreaking findings published in Nature Medicine shows improved outcomes when standard treatments fail Miami, [...]
Publication and Pharma Partners
